Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ista Vitrase sNDA extension

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA's revised action date for Ista's pending sNDA for use of Vitrase (ovine hyaluronidase) as a spreading agent is May 5 following an extension; the original user fee date was Feb. 6 (1Pharmaceutical Approvals Monthly Aug. 1, 2003, In Brief). The extension follows Ista's December amendment containing manufacturing information requested in an April 2003 "approvable" letter. An NDA for vitreous hemorrhage is also pending, with action expected by April 4. Ista recently presented a subset analysis showing greater efficacy in patients with diabetes in the two VH pivotal trials. FDA's Dermatologic & Ophthalmic Drugs Advisory Committee concluded March 17, 2003 that the pivotal data did not demonstrate sufficient efficacy for approval, but agreed that additional subgroup analyses could be used to provide evidence of efficacy...

You may also be interested in...



Ista Vitrase supplement

Ista submits sNDA Aug. 4 for use of its pending ophthalmic solution Vitrase (ovine hyaluronidase) "as a spreading agent to facilitate the dispersion and absorption of other drugs." The firm says it is pursuing the additional indication because of shortages of spreading agents, because no additional studies were needed, and because commercialization efforts could begin while the original NDA for vitreous hemorrhage is reviewed. Vitrase became "approvable" April 3 for treatment of vitreous hemorrhage...

Future Use Of Titanium Dioxide In Spray And Powder Cosmetics Hinges On SCCS Review

As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.

Nanobiotix CEO’s Expansion Plans Target ‘Millions’ Of Patients

Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.

Topics

UsernamePublicRestriction

Register

PS002465

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel